130 related articles for article (PubMed ID: 36470510)
1. Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA).
Prins HAB; Zino L; Svensson EM; Verbon A; de Bree GJ; Prins JM; Reiss P; Burger DM; Rokx C; Colbers A;
Int J Antimicrob Agents; 2023 Jan; 61(1):106697. PubMed ID: 36470510
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.
De Nicolò A; Calcagno A; Motta I; De Vivo E; D'Avolio A; Di Perri G; Wiesner L; Ebrahim IE; Maartens G; Orrell C; McIlleron H
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0013622. PubMed ID: 35583344
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
Larson KB; Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Acosta EP;
J Pediatric Infect Dis Soc; 2016 Jun; 5(2):131-7. PubMed ID: 27199469
[TBL] [Abstract][Full Text] [Related]
4. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
[TBL] [Abstract][Full Text] [Related]
6. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.
Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; Brennan C; de Oliveira CF
J Int AIDS Soc; 2014; 17(4 Suppl 3):19490. PubMed ID: 25393999
[TBL] [Abstract][Full Text] [Related]
7. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
Capetti AF; Cossu MV; Orofino G; Sterrantino G; Cenderello G; De Socio GV; Cattelan AM; Soria A; Rusconi S; Riccardi N; Baldin GM; Niero FP; Barbarini G; Rizzardini G
BMC Infect Dis; 2017 Sep; 17(1):658. PubMed ID: 28964268
[TBL] [Abstract][Full Text] [Related]
8. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Taiwo B; Acosta EP; Ryscavage P; Berzins B; Lu D; Lalezari J; Castro J; Adeyemi O; Kuritzkes DR; Eron JJ; Tsibris A; Swindells S
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):167-73. PubMed ID: 23797691
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
Elliot ER; Cerrone M; Challenger E; Else L; Amara A; Bisdomini E; Khoo S; Owen A; Boffito M
J Antimicrob Chemother; 2019 Jan; 74(1):149-156. PubMed ID: 30272231
[TBL] [Abstract][Full Text] [Related]
10. Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.
Gutierrez-Valencia A; Trujillo-Rodriguez M; Fernandez-Magdaleno T; Espinosa N; Viciana P; López-Cortés LF
J Int AIDS Soc; 2018 Feb; 21(2):. PubMed ID: 29430854
[TBL] [Abstract][Full Text] [Related]
11. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Asienzo J; Kaimal A; Mirembe G; Lugemwa A; Ategeka G; Borok M; Mugerwa H; Siika A; Odongpiny ELA; Castelnuovo B; Kiragga A; Kambugu A;
Lancet HIV; 2022 Jun; 9(6):e381-e393. PubMed ID: 35460601
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
Jackson A; Else L; Higgs C; Karolia Z; Khoo S; Back D; Devitt E; Pozniak A; Boffito M
HIV Clin Trials; 2018 Feb; 19(1):31-37. PubMed ID: 29189101
[TBL] [Abstract][Full Text] [Related]
15. Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.
Foca M; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Britto P; Carey VJ; King J; Acosta EP; Cressey TR;
Pediatr Infect Dis J; 2016 Sep; 35(9):e271-4. PubMed ID: 27187753
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
18. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
[TBL] [Abstract][Full Text] [Related]
19. Darunavir Pharmacokinetics With an Increased Dose During Pregnancy.
Eke AC; Stek AM; Wang J; Kreitchmann R; Shapiro DE; Smith E; Chakhtoura N; Capparelli EV; Mirochnick M; Best BM;
J Acquir Immune Defic Syndr; 2020 Apr; 83(4):373-380. PubMed ID: 31923087
[TBL] [Abstract][Full Text] [Related]
20. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; de Oliveira CF; Brennan C;
Lancet HIV; 2015 Apr; 2(4):e127-36. PubMed ID: 26424673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
